Please login to the form below

Not currently logged in
Email:
Password:

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Those are headed by Mayzent (siponimod) – due to launch in the first quarter of 2019 – which it says is the “first and only drug proven to delay progression” in patients with

Latest news

  • Novartis files for approval of MS drug in EU, US Novartis files for approval of MS drug in EU, US

    Siponimod also seemed to have a meaningful benefit on patients’ cognitive processing speed in the study. ... Siponimod has an opportunity to tap into a niche not fully addressed by rival therapies.

  • Novartis drug works in secondary progressive MS Novartis drug works in secondary progressive MS

    Orally-active siponimod reduces risk of disability progression.  . A follow-up to Novartis' multiple sclerosis therapy Gilenya has been shown to work in a tough-to-treat form of multiple sclerosis ... MS). The new drug candidate - called siponimod

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow

  • Tackling a formidable foe Tackling a formidable foe

    Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics